VIVS
VivoSim Labs, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.16
+0.38%Year over year
Reported trailing growth
- Revenue
- -21.1%
- EBITDA
- —
- EBIT
- +6.7%
- EPS
- —
- Free cash flow
- +3.0%
- Operating cash flow
- +3.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -29.3%
- EBITDA
- —
- EBIT
- +11.0%
- Net income
- —
- EPS
- —
- Free cash flow
- -14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026